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Abstract
Background: This study aimed at verifying the action of multi-walled carbon nanotubes (MWCNT) under the
naturally transformable Neisseria meningitidis against two different DNA obtained from isogenic mutants of this
microorganism, an important pathogen implicated in the genetic horizontal transfer of DNA, causing the escape of
the principal vaccination measured worldwide by the capsular switching process.
Materials and methods: The bacterium receptor strain C2135 was cultivated and had its mutant DNA donor M2
and M6, which received a receptor strain and MWCNT at three different concentrations. The inhibition effect of
DNAse on the DNA in contact with nanoparticles was evaluated.
Results: The results indicated an in increase in the transformation capacity of N. meninigtidis in different
concentrations of MWCNT when compared with negative control without nanotubes. A final analysis of the
interaction between DNA and MWCNT was carried out using Raman Spectroscopy.
Conclusion: These increases in the transformation capacity mediated by MWCNT, in meningococci, indicate the
interaction of these particles with the virulence acquisition of these bacteria, as well as with the increase in the
vaccination escape process.
Introduction
Neisseria meningitidis is a commensal bacterium of the
human upper respiratory tract that may occasionally
provoke invasive infections such as septicemia and
meningitis. It is also naturally competent and therefore
can exchange genetic information with each other by
this process. This natural competence has been directly
correlated to pilliation of these organisms, as well as a
specific uptake sequence, within the genome of these
bacterium [1].
The use of mutations for the study of the capsular
polysaccharide of N. meningitidis is the aim of several
studies of the meningococci pathogenesis [2-4]. The
capsular polysaccharide is the major virulence factor
and a protective antigen. Meningococcal strains are
classified into 12 different serogroups according to their
capsular immune specificity, along with serogroups A, B,
C, Y and W135 are the most frequently found in inva-
sive infections. The capsule of serogroups B, C, Y and
W135 strains is composed of either homopolymers (B
and C) or heteropolymers (Y and W135) of sialic acid-
containing polysaccharides that are specifically linked,
depending on the serogroup [5,6]. This polymerization
is mediated by the polysialyltransferase, encoded by the
siaD gene in strains of serogroups B and C (also called
synD and synE, respectively) and by synG in serogroup
W135. Capsule switching after replacement of synE,i na
serogroup C strain, by synG may result from the conver-
sion of capsule genes by transformation and allelic
recombination [7-10]. Such capsule switching from ser-
ogroup C to B N. meningitidis was observed in several
countries, either spontaneously or after vaccination cam-
paigns [7-13]. It might explain the emergence and the
clonal expansion of strains of serogroup W135 of
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who had been vaccinated against meningococci of ser-
ogroups A and C [14]. These W135 strains belong to
the same clonal complex ET-37/ST-11 as prominent
serogroup C strains involved in outbreaks worldwide
[8,9,15]. Hence, the emergence of these W135 strains in
epidemic conditions raised the question about a possible
capsule switching as an escape mechanism to vaccine-
induced immunity. Also, these events are expected to
occur continuously and can be selected by immune
response against a particular capsular polysaccharide [9].
However, the interference of immune response with
transformation efficacy has not been yet evaluated. Spe-
cific capsular antibodies are expected to bind to the bac-
terial surface and hence they interfere in DNA
recognition and uptake. Also, environmental interfer-
ence under the transformation process of this bacterium
is unknown.
T h i sw o r ka i m e da tt h eu s eo fm u l t i - w a l l e dc a r b o n
nanotubes (MWCNT) for the study of the nanostructures
action on the transformation process of meningococci,
specifically their functions under the capsular switching
process. The methods used in this work aimed at the
action of MWCNT in the transformation of serogroup C
N. meningitidis against two different DNA obtained from
isogenic mutants of this microorganism.
Methods
Synthesis of multi-walled carbon nanotubes
The carbon nanotubes were produced by the process of
hot filament chemical vapor deposition (HFCVD), at the
Nanoengineering and Diamond Laboratory (NanoEng)
of the Department of Semiconductors, Instruments and
Photonics of the UNICAMP School of Electric Engi-
neering and Computer Science. The carbon nanotubes
were made in a copper substrate covered by a conduc-
tive polymer film called polyaniline. The polyaniline film
covering the copper was dried on a hot plate at 100°C.
After that, 0.2 ml of a 2 g/l acetone-diluted nickel
nitrate (Ni(NO3)2) (where the nickel is the catalyzer for
the growth of carbon nanotubes) was dropped on the
dry polyaniline film. After drying, in room temperature,
the polyaniline film was introduced into the HFCVD
reactor in nitrogen atmosphere at 450°C and 27 mbar
pressure for 30 minutes of growth time. An acetone
solution of camphor bubbled in hydrogen gas was used
as source of carbon. Morphological analyses were made
by FESEM (Field Emission Scanning Electron Micro-
scopy) using a JEOL JSM-6330F operated at 5 KV, 8 μA,
and HRTEM (High Resolution Transmission Electron
Microscopy) using a JEOL JSM 3010 operated at 300
KV and 73 μA. Figure 1 shows typical images of FESEM
and HRTEM. We also used other nanostructures to
confirm our results as the NC nanotubes (commercially
obtained from Helix Material Solutions, USA), the NT2
were described by Grecco et al. [16].
Bacterial Strains and Media
The characteristics of the strains used in this study are
described in Table 1. They were grown at 37°C under 5%
of CO2 on GCB agar medium (Difco) containing the sup-
plements described by Lancellotti et al. [9]. When needed,
culture media were supplemented with erythromycin at 2
μg/ml and spectomycin at 40 μg/ml. Escherichia coli
strains used for plasmid preparations were DH5a [17].
DNA Techniques
Recombinant DNA protocols and transformation were
performed as described previously [18]. The oligonu-
cleotides used are listed in Table 2. All the mutants
Figure 1 shows (a) the morphologic by SEM and (b) structure by HRTEM of typical as deposited MWCNTs. Scale bars are indicated, the
outer diameter is ca. 200 nm and length > 1500 nm for the MWCNT show in (a). Multi-walled structures are presented in (b) corresponding to a
MWCNT with outer diameter of ca. 20 nm.
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by Polymerization Chain Reaction - PCR analysis using
an oligonucleotide harboring the target gene and
another harboring the cassette.
Construction of NMB0065 mutant by polar mutation
This mutant construction follows the specifications
described by Hollanda et al. [18]. Briefly, the NMB0065
sequence from N. meningitidis C2135 was amplified
using 03.12-3 and 03.12-4 oligonucleotides (table 2).
This fragment was cloned into the pGEM-T Easy Vector
System II (Promega Corporation, Madison, WI, USA), to
generate the plasmid pLAN6. E. coli strain Z501 was
transformed with plasmid pLAN6 resulting in the plas-
mid pLAN7. The ΩaaDA cassette was inserted into the
BclI site of pLAN7 to generate plasmid pLAN45, which
was transformed into the C2135 strain, generating the
mutant strain M2 (Figure 2).
Construction of serogroup W135 mutants in
transcriptional fusion synG::ermAM
As the mutant M2, this mutant construction follows the
specifications described in Hollanda et al. [18]. Briefly,
the synG gene responsible for the synthesis of the W135
capsule was amplified using the 98-30 and 03-12-5 oli-
gonucleotides (table 2) from the serogroup W135 strain
W135ATCC. The amplified fragment was cloned into
the pGEM-T Easy Vector System I (Promega, Madison,
WI, USA), to generate the plasmid pLAN11 (Figure 3).
Another fragment was amplified using the 04-02-2/
galECK29A from synG downstream sequence, cloned
into pGEM-T Easy Vector, to generate pLAN52. The
ermAM cassette was amplified by ERAM1/ERAM3 and
inserted into NcoI site of pLAN52 to generate pLAN53.
The fragment amplified from pLAN53 with the ERAM1
and galECK29A [19] was inserted into PstIs i t eo f
pLAN11 to generate pLAN13-2. This plasmid was line-
arised by the enzyme SphI and transformed into
W135ATCC strain to generate the synG::ermAM fusioned
strain M6, erythromycin resistant.
Analysis of transformation frequency up to MWCNT
contact
At 1.10
8 colony-forming units - CFU - of the receptor
strain C2135, we added 1 μgg e n o m i cD N Af r o mM 2
and M6 mutants and 10, 20 and 50 μg of different
MWCNT. A negative control was also performed with-
out MWCNT. The suspension was incubated for three
hours at 37°C in atmosphere of 5% of CO2 by three
hours. The counts of total CFU were performed in GCB
spectinomycin or erythromycin plates in triplicate analy-
sis (for M2 and M6 isogenic mutants, respectively). The
Table 1 Bacterial Strains used in this work
Strain Characteristics Origin (Reference)
DH5∝ Escherichia coli F-, endA1, hsdR17 c, supE44, thi-1, gir A96, relA1 [17]
pLAN45 Plasmid containing ΔNMB0065::ΩaaDA derivated from pGEMTEasy [18]
pLAN13 Plasmid containing the fusion of synG::ermAM [18]
C2135 Neisseria meningitidis serogroup C, BIOMERIEUX INCQS - FIOCRUZ
W135ATCC Neisseria meningitidis serogroup W135, ATCC35559 INCQS - FIOCRUZ
M2 N.meningitidis isogenic mutant ΔNMB0065::ΩaaDA [18]
M6 N.meningitidis W135ATCC transformed with pLAN13 to generate a fusioned strain synG:ermAM [18]
Table 2 Oligonucleotides used in this work
Oligonucleotide Sequence 5’-3’ Description
03.12-3 TGCGGATCCGCAGTAATTTTATCGGTTGG NMB0065 forward
03.12-4 CCCCACTACCTAAAAAATGCTGATTTG NMB0065 reverse
aadA1 TGCCGTCACGCAACTGGTCCA ΩaaDA forward
aadA2 CAACTGATCTGCGCGCGAGGC ΩaaDA reverse
98.30 GGTGAATCTTCCGAGCAGGAAA synG forward
98.31 AAAGCTGCGCGGAAGAATAGTG synG reverse
03.12-5* TCGGGATCCTTATTTTTCTTGGCCAAAAA synG reverse
04.02-1 CAATGAATCTCGCGTTGCTGTAGGTG synG forward
04.02-2 GAAAAATAATTTGGGGCTTAGG synG forward
galECK29A CTTCCATCATTTGTGCAAGGCTGC galE reverse
ERAM1 GCAAACTTAAGAGTGTGTTGATAG ermAM forward
ERAM3 AAGCTTGCCGTCTGAATGGGACCTCTTTA GCTTCTTGG ermAM reverse
*The underlined sequences in italic are the insertion of the BamHI site into original sequence
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were analyzed by PCR for the presence of target gene
transfer in the transforming units (ΩaaDA cassette for
the M2 DNA and synG for M6 donor DNA). In order
to verify the interaction between DNA, MWCNT and
D N A s ea c t i o n ,t h es a m ea m o u n t so fD N A ( 1μg) from
M2 and M6 mutants, MWCNT (20 μg) and bacterial
cells were submitted to action 5 U of DNase (New Eng-
land Biolabs, UK) and further transformation process.
Also, the counts of cfu were performed in GCB specti-
nomycin or erythromycin plates in triplicate analysis
(for M2 and M6 isogenic mutants respectively).
Analysis of interaction between DNA and MWCNT by
Raman spectroscopy
The prior analysis of DNA from M2 and M6 mutant
strains with MWCNT was performed under a mix of 1
μgo fM 6g e n o m i cD N Aa n d2 0μgo fM W C N T .T h e
samples were characterized by Raman spectroscopy
[20,21]. The spectra were recorded at room tempera-
ture using a Renishaw microprobe in Via system,
employing an UV laser for excitation (l =3 2 5n m )
at about 10 mW. The samples M2 and M6 were
dripped onto a quartz substrate for UV laser Raman
spectroscopy.
NMB0065
pLAN45
aaDA
pLAN7
03.12.3
03.12.4
BclI site
03.12.3 03.12.4
pLAN6
03.12.3
03.12.4
BclI site
03.12.3
03.12.4
Cloning in pGEMT Easy Vector
Strain dam- for digestion of BclI site
Insertion of aaDA cassette in BclI site
siaB siaA siaC galE siaE 0065 C2135
(α α α α2-9) N-acetyl neuraminic acid syntheis operon 
BclI site
M2
NMB0065 aaDA
Mutant M2
Figure 2 shows schematic representation of the capsule genes of C serogroup in disrupted construction of NMB0065 gene with aaDA
cassette. The NMB0065 gene was amplified using the 03-12-3 and 03-12-4 oligonucleotides (table 3) from C2135 strain. This fragment was
cloned into the pGEM-T Easy Vector System II (Promega Corporation, USA), to generate the plasmid pLAN6. E. coli strain Z501 was transformed
with plasmid pLAN6 resulting in the plasmid pLAN7. The ΩaaDA cassette was inserted into the BclI site of pLAN7 to generate plasmid pLAN45,
which was transformed into the C2135 strain to generate the isogenic mutant strain M2 [18,19].
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The effects of the MWCNT were verified by an increase
in the number of CFU obtained from many transforma-
tion processes. The CFU number resulting from the
transformation process using DNA from M2 donor
strain was higher than the one obtained using M6 as
the donor strain. Also, the use of three different
MWCNT and three different concentrations (10, 20 and
50 μg of each MWCNT) showed an increase in the
number of CFU resulted from the transformation pro-
cess using both DNA donor strains (Figure 4(c-d) and
table 3).
The intention of two different DNA donors was to
certificate the independence of MWCNT action under
t h es a m eb a c t e r i a ls t r a i n-N. meningitidis C2135.
Further analysis by PCR demonstrated the transfer of
the tagged gene from M2 and M6 in transformed strains
(data not shown). The Raman analysis showed the inter-
action of MWCNT with the DNA obtained from M6
mutant strains as viewed in Figure 4(a-b).
Data analyses were made by ratio values between the
numbers of transformants cfu obtained with MWCNT
by median values of transformants cfu obtained without
nanotubes treatment (Figures 4c-d and table 3). The
values were analyzed by one-way analysis of variance
ANOVA (Tukey’s test compared each treatment to con-
trol without nanoparticles in transformation, considering
significant values of P > 0.05). Some values obtained
with commercial MWCNT - NC and NT2 showed dif-
ferent results when compared with NT1 (table 3 and
Figure 4).
The relations between the meningococci transforma-
tion and MWCNT action viewed in these results could
mimic the presence of carbon nanoparticles in atmo-
sphere and evoke the emergence of outbreaks of Brazi-
lian purpuric fever (BPF) caused by another naturally
competent bacteria, Haemophilus influenzae biogroup
aegyptius [22,23]. The Haemophilus influenzae biotype
aegyptius causes BPF, a dangerous inflammatory disease
known as purpura fulminans with a great mortality rate
ctrD ctrC ctrB ctrA synB synA synC galE
BclI PstI EcoRI EcoRI ClaI ClaI ClaI SalI
04.03(8)
98.30 98.31
04.02(1) 04.02(2) 04.02(3) 03.12(5)
M6
04.05(1) 04.05(2) 04.05(4) 04.05(3) 04.05(6) 04.05(5)
synG
pLAN53
ERAM3
galECK
pLAN11
PstI site
galECKA
pLAN13
ERAM3
galECKA
galE synG
Insertion in PstI site
ermAM Mutant M6
Figure 3 Schematic representation of the capsule genes of W135 serogroup in transcriptional fusion of synG with ermAM cassette. The
synG gene responsible for the synthesis of the W135 capsule was amplified using the 98-30 and 03-12-5 oligonucleotides (table 2) from
W135ATCC strain. The amplified fragment was cloned into the pGEM-T Easy Vector System I (Promega, Madison, WI, USA), to generate the
plasmid pLAN11. In the same conditions, another fragment was amplified using the 04.02-2/galECK29A from synG downstream sequence to
generate pLAN52. The ermAM cassette was inserted into NcoI site of pLAN52 to generate pLAN53. The fragment amplified from pLAN53 with
the ERAM1 and galECK29A [19] was inserted into PstI site of pLAN11 to generate pLAN13-2. This plasmid was linearised by the enzyme SphI and
transformed into W135ATCC strain to generate the synG::ermAM strain M6, erythromycin resistant [18].
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Figure 4 shows signal of DNA in the region until 2000 cm
-1. DNA consist of three groups: phosphates, deoxyribose and four bases such as
A (adenine), T (thymine), C (cytosine) and G (guanine). In our work, the bands could be assigned to 883/1098/1045 cm
-1 - O-P-O backbone;
1276 cm
-1 - C (cytosine); 1456 cm
-1- A (adenine);1602 cm
-1 - guanine (G) and 1670 cm
- - T (thymine). The bands of DNA donor M2 (a) and M6
(b) are in accordance with some authors [21,22]. The bands 2739-3421 cm
-1 are not assigned to DNA, it is assigned to the quartz substrate. In (c)
and (d) it shows the action of the MWCNT under Neisseria meningitidis strain C2135 using as donor DNA the M2 (c) and M6 (d).
Table 3 Values obtained from C21 35 transformation using the donor DNA from M2 and M6 mutants.
Donor DNA (1 μg) Ratio (means obtained exposed to MWCNT/mean of negative
control)
P values (one way Tukey’s test)
Negative Control (without MWCNT) M2 1.02 ± 0.17
NT1 (10 μg) 0.89 ± 0.09 P = 0, 1631 (non significant)
NT1 (20 μg) 2.24 ± 0.70 P < 0, 05 (P = 0, 0496 significant)
NT1 (50 μg) 3.52 ± 0.50 P < 0, 05 (P = 0, 0073 very
significant)
NC (10 μg) 0.85 ± 0.50 P = 0, 3166 (non significant)
NC (20 μg) 2.18 ± 0.90 P = 0, 0798 (non significant)
NC (50 μg) 4.36 ± 1.18 P < 0, 05 (P < 0, 0020 significant)
NT2 (20 μg) 1.42 ± 0.13 P < 0, 05 (P = 0, 0240 significant)
Negative Control (without mesoporous
siliM6
1.09 ± 0.25
NT1 (10 μg) 1.71 ± 0.25 P < 0, 05 (P = 0, 0385 significant)
NT1 (20 μg) 2.03 ± 0.08 P < 0, 05 (P = 0, 0034 very
significant)
NT1 (50 μg) 2.11 ± 0.30 P < 0, 05 (P = 0, 0106 significant)
NC (10 μg) 2.03 ± 0.35 P < 0, 05 (P = 0, 0193 significant)
NC (20 μg) 2.44 ± 0.88 P < 0, 05 (P = 0, 0490 significant)
NC (50 μg) 2.14 ± 0.49 P < 0, 05 (P = 0, 0403 significant)
NT2 (20 μg) 5.58 ± 0.86 P < 0, 05 (P = 0, 0065 very
significant)
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Page 6 of 9[24]. Kroll et al. [24] described these Haemophilus influ-
enzae strains, usually associated with conjunctivitis
cases, as a product of horizontal transfer between N.
meningitidis and Haemophilus influenzae.I nt h es a m e
geographic region of these outbreaks, the primitive agri-
cultural practice, performed by burning sugar cane, gen-
erates an emission of carbon micro and nanoparticles in
the atmosphere, potentially provoking respiratory disor-
ders by particles inhalation [25]. Our group has been
studying these bacteria and testing them with MWCNT
on its transformation process.
This process is similar to the phenomena of capsular
switching as described in sub Saharan African [26-28]
and Saudi Arabian regions (Hajj pilgrimage) [26,29-35].
In desert zones, the ramarthan wind and the presence
of silica nanostructures facilitates the capsular switching
process in meningococci strains [26,29-36]. Thus, new
experiments using animal models that could confirm
this hypothesis have been performed by our group. Also,
the increases in the transformation capacity in bacteria
have been verified in Escherichia coli by nanotube struc-
tures, as described by Rojas-Chapana et al. [37].
T h er e s u l t so fD N A s ei n h i b i t i o no v e rf r e eD N A
(Figure 5) could explain the protection of the bacterial
g e n e sb yM W C N Tc o n t a c ti nt h i sn a n o s t r u c t u r e .T h i s
evidence is showed in the graphic of Figure 5 with the
increase of CFU in the test containing DNAse-treated
DNA and exposed to 20 μg of MWCNT. These results
need further experiments in order to better understand
this interaction between bacterial compounds and the
transformation system (represented in Figure 5).
Furthermore, animal models, for these studies, may be
very interesting for future assessments of atmospheric
contamination by carbon nanoparticles produced by pri-
mitive agriculture and carbon miners.
This work indicated, for the first time in scientific lit-
erature, that the action of atmospheric nanoparticles
obtained from anthropic activities, such as primitive
agriculture, influences the bacterial transformation
process.
DNAse
DNAse complex
With DNA
DNA destruction
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MWCNT bound in DNA
Protection of DNA
A
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Figure 5 Schematic representation of the inhibitor effect of the DNase by MWCNT. (a) the transformation bacterial complex formed by
many proteins as pilQ, pilE, ComA, and accessory proteins distributed around the outer membrane (OM), periplasmatic space (PS) and inner
membrane (IM) in naturally transformable Gram negative bacteria, specially Neisseria species [38]. (b) Graph showing the inhibitory effect of
MWCNT in DNase avoiding the DNA lyses.
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The increase in the transformation capacity mediated by
MWCNT in meningococci indicates an interaction of
these particles with the bacterial DNA leading to viru-
lence acquisition and an increase in the escape to vacci-
nation. The presence of these nanoparticles protects the
DNA from DNAse action, increasing the recombination
frequency. These results show that important measures
for public health, in places where the MWCNT or car-
bon microparticles are produced, need to be carefully
revised.
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